Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Indiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 32 | 7,455 | 35% |
| 2020 | 35 | 7,841 | 39% |
| 2021 | 30 | 9,085 | 44% |
| 2022 | 42 | 9,886 | 47% |
| 2023 | 34 | 10,101 | 51% |
| 2024 | 43 | 11,035 | 53% |
| 2025 from claims | – | 9,502 8,720–10,053 | 54% |
| 2026 forecast | – | 9,947 8,752–11,479 | 55% |
| 2027 forecast | – | 10,398 8,889–12,391 | 55% |
| 2028 forecast | – | 10,866 9,067–13,306 | 56% |
| 2029 forecast | – | 11,355 9,274–14,240 | 57% |
| 2030 forecast | – | 11,863 9,504–15,202 | 57% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 54% of the cases CMS names in Indiana; 24 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 1% inpatient hospital, 60% hospital outpatient, 38% office. The share outside the hospital has moved +18 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~9,900 | ~130 | ~6,000 | ~3,800 |
| 2027 · ~10,400 | ~150 | ~6,200 | ~4,000 |
| 2028 · ~10,900 | ~160 | ~6,500 | ~4,200 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 83 | 23,783+12%/yr | +12%/yr | 11.5 | 50% | 36,600 in 2030+7.5%/yr |
| Ohio | 39 | 12,139+7.6%/yr | +7.6%/yr | 6.3 | 47% | 15,800 in 2030+4.5%/yr |
| Michigan | 37 | 10,345+8%/yr | +8%/yr | 6.5 | 46% | 13,300 in 2030+4.3%/yr |
| Kansas | 36 | 8,726+10%/yr | +10%/yr | 16.1 | 71% | 13,300 in 2030+7.2%/yr |
| Missouri | 32 | 8,053+4.4%/yr | +4.4%/yr | 7.7 | 47% | 8,660 in 2030+1.2%/yr |
| Minnesota | 15 | 3,990+14%/yr | +14%/yr | 4.8 | 50% | 5,210 in 2030+4.5%/yr |
| Wisconsin | 12 | 3,903−0.1%/yr | −0.1%/yr | 3.9 | 25% | 4,360 in 2030+1.8%/yr |
| Iowa | 5 | 3,495−1.6%/yr | −1.6%/yr | 5.7 | 40% | 2,680 in 2030−4.3%/yr |
| Nebraska | 10 | 2,307+4.5%/yr | +4.5%/yr | 6.6 | 54% | 3,570 in 2030+7.5%/yr |
| South Dakota | 7 | 1,064−2.8%/yr | −2.8%/yr | 6.0 | 16% | 1,440 in 2030+5.1%/yr |
| North Dakota | 1 | 700+2.6%/yr | +2.6%/yr | 5.2 | 34% | 600 in 2030−2.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 343 | 70,8340%/yr | 0%/yr | 96.11.2× | 30% | 77,200 in 2030+1.4%/yr |
| Bone graft & orthobiologics | 13 | 404−19%/yr | −19%/yr | 0.60.8× | 0% | 330 in 2030−3.2%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Indiana · Every state · Compare with Illinois
Convatec leads with 49% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 29 companies reported engagement with Indiana’s surgeons worth $414K in consulting, speaking, meals and travel tied to these products, about $9,621 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.